Latest Posts



Mar 24

Partex NV announces collaboration with Althea DRF Lifesciences to provide comprehensive end-to-end services to accelerate drug discovery and development

Frankfurt, Germany; 28 March 2024 – Partex Group, a pioneer in AI-driven drug discovery, announces a collaboration with Althea DRF...
Read More


Mar 24

Innovative AI technology in oncology: Partex Group presents results from a pilot project

During the German Cancer Congress 2024 in Berlin, the companies Innoplexus AG /Amrit AG, companies of Partex N.V., presented the...
Read More

Innoplexus wins Horizon Interactive Gold Award for Curia App

Read More

Innoplexus Consulting Services is Proud to Announce ISO/IEC 27001:2013 Certification

Pune, India, February 13, 2020 – Innoplexus Consulting Services Private Limited, a subsidiary of Innoplexus AG, is delighted to have been awarded ISO/IEC 27001:2013 certification, a global standard for reducing the risk and improving the security of data. Innoplexus has been committed to achieving the highest levels of security compliance. This accreditation further cements Innoplexus’ efforts to maximize protection of its clients’ and key stakeholders’ valuable data and information assets.

Commitment to Continuous Improvement

Innoplexus is committed to continually improving its Information Security Management System (ISMS). The implementation team based in Pune, India, underwent an extensive company-wide audit that included a process-based approach for establishing, implementing, operating, monitoring, maintaining, and improving ISMS.

ISO is one of the most well-respected global standards. Innoplexus was audited by Perry Johnson Registrars and was presented with its certificate on 13th February 2020.

Innoplexus Consulting Services Managing director, Abhijit Keskar said, “Achieving ISO/IEC 27001:2013 certification is fantastic news and means our customers have complete assurance that their confidential information is secure with us.” He thanked the project team adding, “It proves theirs and the company’s commitment to ensuring the best ISMS for our clients.”

Innoplexus is a leading global AI-technology solution provider with over 300 employees and 100+ patent applications including 12 grants in artificial intelligence, machine learning, and blockchain technologies. Innoplexus applies its proprietary tech stack at all stages of the drug development value chain, through smart Data as a Service (DaaS) and Continuous Analytics as a Service (CAaS) solutions. These solutions can generate real-time insights from hundreds of terabytes of structured and unstructured private and public data, thereby facilitating continuous, informed decision-making for its customer base. Founded in 2015, Innoplexus AG is headquartered in Eschborn, Germany, with offices in Pune, India, as well as Iselin, and San Francisco, United States.

Featured News

Strategic partnership announcement: Innoplexus holding company Partex NV is pleased to announce a one-of-its-kind collaboration with Anavex Life science corp. for Artificial Intelligence (AI) enabled drug development and healthcare sales marketing anavex_partex_partnership_Innoplexus

Strategic partnership announcement: Innoplexus holding company Partex NV is pleased

Exciting News! Anavex Life Sciences and Partex NV Announce Strategic Partnership to Enhance Patient Experience. Anavex Life Sciences Corp. and Partex NV N.V. Group are pleased to announce…